Loading clinical trials...
Loading clinical trials...
Parasternal Intercostal Muscle Thickening as an Additive Weaning Criterion to Minimize Re-intubation Rate: a Randomized Controlled Trial
Increased days of MV are not without hazards, including barotraumas and ventilator-associated pneumonia. Similarly, premature separation of MV is associated with increased mortality secondary to adverse cardiorespiratory events. Therefore, the time of weaning should be wisely evaluated. There is growing evidence concerning respiratory muscles dysfunction that contributes to difficulty or prolonged liberation from MV.
Researchers aim to evaluate the influence of adding parasternal thickening fraction to the standard weaning criteria and its impact on reintubation
Age
18 - 65 years
Sex
ALL
Healthy Volunteers
No
Cairo University
Cairo, Giza Governorate, Egypt
Start Date
September 1, 2025
Primary Completion Date
August 1, 2026
Completion Date
August 31, 2026
Last Updated
September 8, 2025
200
ESTIMATED participants
Parasternal intercostal thickening fraction
DEVICE
Sham parasternal intercostal thickening
DEVICE
Lead Sponsor
Cairo University
NCT07448805
NCT07222007
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions